Sumitomo Mitsui DS Asset Management Company Ltd Buys 3,377 Shares of Eli Lilly and Company (NYSE:LLY)

Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 124,781 shares of the company's stock after purchasing an additional 3,377 shares during the quarter. Eli Lilly and Company comprises 1.1% of Sumitomo Mitsui DS Asset Management Company Ltd's portfolio, making the stock its 15th largest position. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Eli Lilly and Company were worth $103,058,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. WestEnd Advisors LLC lifted its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares in the last quarter. Citizens National Bank Trust Department raised its holdings in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the last quarter. Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company in the 4th quarter valued at approximately $43,000. Prudent Man Investment Management Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $48,000. Finally, Highline Wealth Partners LLC boosted its stake in Eli Lilly and Company by 53.3% during the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after purchasing an additional 24 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $0.32 on Thursday, hitting $779.60. 1,450,772 shares of the company traded hands, compared to its average volume of 3,662,501. The business's 50 day moving average price is $777.35 and its 200-day moving average price is $799.71. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $738.85 billion, a price-to-earnings ratio of 63.43, a P/E/G ratio of 1.13 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.58 earnings per share. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's payout ratio is presently 48.82%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LLY. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. Finally, UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,011.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.